T1	Condition 13 25	hypertension
T2	Condition 29 46	metabolic disease
T3	Qualifier 0 12	Uncontrolled
*	OR T1 T2
T4	Scope 13 46	hypertension or metabolic disease
R1	Has_qualifier Arg1:T4 Arg2:T3	
T5	Condition 48 75	Neurodegenerative disorders
T6	Condition 82 99	Parkinson disease
T7	Condition 101 104	LBD
T8	Condition 109 112	FTD
*	OR T7 T8 T6
T9	Scope 82 112	Parkinson disease. LBD, or FTD
R2	Subsumes Arg1:T5 Arg2:T9	
T10	Condition 116 124	Dementia
T11	Condition 128 153	Mild cognitive impairment
T12	Measurement 133 153	cognitive impairment
T13	Value 128 132	Mild
R3	Has_value Arg1:T12 Arg2:T13	
R4	multi Arg1:T11 Arg2:T12	
T14	Temporal 154 165	at baseline
*	OR T10 T11
T15	Scope 116 153	Dementia or Mild cognitive impairment
R5	Has_temporal Arg1:T15 Arg2:T14	
T16	Condition 167 193	Long life major depression
T17	Measurement 195 210	Baseline scores
T18	Value 211 214	=16
T19	Measurement 222 255	17-item Hamilton Depression Scale
T20	Temporal 256 267	at baseline
T21	Reference_point 259 267	baseline
R6	Has_index Arg1:T20 Arg2:T21	
R7	Has_temporal Arg1:T19 Arg2:T20	
R8	Has_value Arg1:T19 Arg2:T18	
R9	Subsumes Arg1:T19 Arg2:T17	
R10	AND Arg1:T16 Arg2:T19	
T22	Condition 270 303	Long-life DSM-IV axis 1 disorders
T23	Condition 306 324	Mental retardation
T24	Condition 327 342	Substance abuse
T25	Temporal 345 355	Concurrent
T26	Drug 356 366	medication
T27	Qualifier 367 412	limiting validity of neuropsychological tests
T28	Qualifier 367 387;416 423	limiting validity of imaging
*	OR T28 T27
R11	AND Arg1:T25 Arg2:T26	
T29	Scope 367 423	limiting validity of neuropsychological tests or imaging
R12	Has_scope Arg1:T25 Arg2:T29	
T30	Drug 426 442	Anti-depressants
T31	Qualifier 448 475	anti-cholinergic properties
R13	Has_qualifier Arg1:T30 Arg2:T31	
T32	Drug 448 464	anti-cholinergic
R14	multi Arg1:T31 Arg2:T32	
T33	Drug 477 512	Monoamine oxidase inhibitors (MAOi)
T34	Drug 529 548	narcotic analgesics
T35	Multiplier 550 567	>2 doses per week
T36	Multiplier 514 525	Regular use
R15	Subsumes Arg1:T36 Arg2:T35	
R16	Has_multiplier Arg1:T34 Arg2:T36	
T37	Drug 578 590	neuroleptics
T38	Drug 599 624	anti-dementia medications
T39	Drug 626 633	Aricept
T40	Drug 635 641	Exelon
T41	Drug 643 651	Razadyne
*	OR T41 T40 T39
T42	Scope 626 651	Aricept, Exelon, Razadyne
R17	Subsumes Arg1:T38 Arg2:T42	
T43	Drug 657 666	memantine
T44	Drug 668 675	Namenda
R18	Subsumes Arg1:T43 Arg2:T44	
*	OR T38 T43 T45
T45	Drug 681 710	anti-Parkinsonian medications
T46	Drug 712 719	Sinemet
T47	Drug 721 731	amantadine
T48	Drug 733 746	bromocriptine
T49	Drug 748 757	pergolide
T50	Drug 759 769	selegeline
*	OR T50 T49 T48 T47 T46
T51	Scope 712 769	Sinemet, amantadine, bromocriptine, pergolide, selegeline
R19	Subsumes Arg1:T45 Arg2:T51	
T52	Drug 792 825;840 851	over the counter memory enhancing medications
T53	Drug 792 815;829 851	over the counter memory protecting medications
T54	Drug 858 871	ginkgo biloba
T55	Drug 873 881	vitamins
*	OR T54 T55
T56	Scope 858 881	ginkgo biloba, vitamins
T57	Scope 792 851	over the counter memory enhancing or protecting medications
R20	Subsumes Arg1:T57 Arg2:T56	
T58	Non-representable 773 900	Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.
T59	Device 912 927	medical devices
T60	Procedure 955 966	MRI imaging
T61	Qualifier 937 966	incompatible with MRI imaging
R21	multi Arg1:T61 Arg2:T60	
R22	Has_qualifier Arg1:T59 Arg2:T61	
T62	Measurement 969 988	Radiation exposures
T63	Value 989 1023	exceeding annual Rad Worker limits
R23	Has_value Arg1:T62 Arg2:T63	
T64	Condition 1026 1039	Heart failure
T65	Measurement 1040 1045	stage
T66	Value 1046 1047	D
R24	Has_value Arg1:T65 Arg2:T66	
T68	Qualifier 1062 1088	American Heart Association
T69	Condition 1095 1117	Chronic kidney disease
T70	Measurement 1121 1127	stages
T71	Value 1128 1131	= 4
T72	Qualifier 1148 1174	National Kidney Foundation
R25	Has_qualifier Arg1:T65 Arg2:T68	
R26	AND Arg1:T64 Arg2:T65	
R27	Has_value Arg1:T70 Arg2:T71	
R28	AND Arg1:T69 Arg2:T70	
R29	Has_qualifier Arg1:T70 Arg2:T72	
T67	Condition 1181 1192	Brain tumor
T73	Condition 1203 1223	neoplastic disorders
T74	Qualifier 1224 1241	outside the brain
R30	Has_qualifier Arg1:T73 Arg2:T74	
T75	Qualifier 1309 1341	likely to affect brain structure
T76	Qualifier 1309 1331;1345 1353	likely to affect brain function
*	OR T76 T75
T77	Procedure 1281 1290	radiation
T78	Procedure 1292 1304	chemotherapy
*	OR T67 T73 T77 T78
T79	Scope 1181 1305	Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy)
T80	Scope 1310 1353	ikely to affect brain structure or function
R31	Subsumes Arg1:T79 Arg2:T80	
T81	Condition 1356 1362	Stroke
T82	Condition 1435 1454	circulation infarct
T83	Qualifier 1425 1434	posterior
T84	Qualifier 1389 1403	total anterior
T85	Qualifier 1405 1421	partial anterior
*	OR T83 T85 T84
T86	Scope 1389 1434	total anterior, partial anterior or posterior
R32	Has_scope Arg1:T82 Arg2:T86	
T87	Measurement 1472 1518	Oxford Community Stroke Project classification
R33	AND Arg1:T87 Arg2:T82	
R34	AND Arg1:T81 Arg2:T87	
T88	Non-representable 1520 1623	Patients with clinically silent of lacunar strokes and transient ischemic attacks will not be excluded.
T89	Qualifier 1625 1636	Significant
T90	Condition 1637 1648	head trauma
R35	Has_qualifier Arg1:T90 Arg2:T89	
T91	Condition 1651 1664	Hydrocephalus
T92	Observation 1680 1700	refusal to cooperate
T93	Observation 1667 1676	Hostility
*	OR T93 T92
